Late recurrence after surgery for cholangiocarcinoma: Implications for follow-up?

Hepatobiliary and Pancreatic Diseases International

Volumn 7, Issue 5, 2008, Pages 544-546

  Thomas, Harun ^a   Heaton, Nigel David ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cholangiocarcinoma; Late recurrence; Long term survivors

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE;

ADJUVANT THERAPY; ADULT; ARTICLE; BILE DUCT CARCINOMA; BONE METASTASIS; BONE RADIOGRAPHY; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE COURSE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FATALITY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAPAROTOMY; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; OBSTRUCTIVE JAUNDICE; PANCREATICODUODENECTOMY; RECURRENT CANCER; SURVIVAL TIME; TUMOR BIOPSY; TUMOR LOCALIZATION; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT SURGICAL PROCEDURES; BONE NEOPLASMS; CELL DIFFERENTIATION; CHEMOTHERAPY, ADJUVANT; CHOLANGIOCARCINOMA; FATAL OUTCOME; HUMANS; LIVER NEOPLASMS; MALE; NEOPLASM INVASIVENESS; PALLIATIVE CARE; RADIOTHERAPY, ADJUVANT; TIME FACTORS;

EID: 55049102379     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin 1996;46:5-27.
2. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002;51:VI1-9.
3. Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG, et al. Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 2005;241:77-84.
4. Jarnagin WR. Cholangiocarcinoma of the extrahepatic bile ducts. Semin Surg Oncol 2000;19:156-176.
5. Wakai T, Shirai Y, Moroda T, Yokoyama N, Hatakeyama K. Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma. Cancer 2005;103:1210-1216.
6. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998;227:821-831.
7. Nakanishi Y, Kondo S, Hirano S, Ambo Y, Tanaka E, Morikawa T, et al. Recurrence of mucosal carcinoma of the bile duct, with superficial flat spread, 12 years after operation. J Hepatobiliary Pancreat Surg 2006;13:355-358.
8. Sasaki T, Kondo S, Ambo Y, Hirano S, Sichinohe T, Kaga K, et al. Local recurrence at hepaticojejunostomy 9 years after resection of bile duct cancer with superficial flat spread. J Hepatobiliary Pancreat Surg 2006;13:458-462.
9. Tanaka N, Nobori M, Kohzuma T, Suzuki Y, Saiki S. Anastomotic recurrence at hepaticojejunostomy in a long-term survivor of bile duct carcinoma: report of a case. Surg Today 1994;24:280-284.
10. Song GW, Lee SG, Lee YJ, Park KM, Hwang S, Kim KH, et al. Analysis of survival and factors affecting the survival after surgical resection of peripheral cholangiocarcinoma: 318 cases in single institute. Korean J Hepatol 2007;13:208-221.
11. Pascher A, Jonas S, Neuhaus P. Intrahepatic cholangiocarcinoma: indication for transplantation. J Hepatobiliary Pancreat Surg 2003;10:282-287.
12. Yano Y, Yamamoto J, Kosuge T, Sakamoto Y, Yamasaki S, Shimada K, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol 2003;33:283-287.
13. Nimura Y, Kamiya J, Kondo S, Nagino M, Uesaka K, Oda K, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience. J Hepatobiliary Pancreat Surg 2000;7:155-162.
14. Tsao JI, Nimura Y, Kamiya J, Hayakawa N, Kondo S, Nagino M, et al. Management of hilar cholangiocarcinoma: comparison of an American and a Japanese experience. Ann Surg 2000;232:166-174.
15. Shimoda M, Kubota K. Multi-disciplinary treatment for cholangiocellular carcinoma. World J Gastroenterol 2007; 13:1500-1504.
16. Dingle BH, Rumble RB, Brouwers MC; Cancer Care Ontario's Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group. The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review. Can J Gastroenterol 2005;19:711-716.
17. Shimizu T, Yokomuro S, Mizuguchi Y, Kawahigashi Y, Arima Y, Taniai N, et al. Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth. World J Gastroenterol 2006;12:6316-6324.
18. Li ZY, Zou SQ. Fas counterattack in cholangiocarcinoma: a mechanism for immune evasion in human hilar cholangiocarcinomas. World J Gastroenterol 2001;7:860-863.